KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Other Accumulated Expenses data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 60.7% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, down 60.7%, while the annual FY2024 figure was $3.4 million, 69.31% down from the prior year.
  • Other Accumulated Expenses reached $5.0 million in Q3 2025 per ACAD's latest filing, down from $13.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $13.4 million in Q2 2025 and bottomed at $2.7 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $6.9 million, with a median of $5.9 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 307.53% in 2023, then plummeted 69.31% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.7 million in 2021, then grew by 0.82% to $2.7 million in 2022, then skyrocketed by 307.53% to $11.0 million in 2023, then tumbled by 69.31% to $3.4 million in 2024, then soared by 47.65% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $5.0 million in Q3 2025, $13.4 million in Q2 2025, and $9.3 million in Q1 2025.